

# Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application (Diagnostics (Clinical, PoC), Research (Proteomic, Genomics, Cell), Therapeutics (Drug Delivery, Wearables)), End User- Global Forecast to 2029

Market Report | 2025-02-01 | 365 pages | MarketsandMarkets

#### **AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

### **Report description:**

The Microfluidics market is projected to reach USD 32.67 Billion by 2029 from USD 22.43 Billion in 2024, growing at a CAGR of 7.8% during the forecast period. The market for microfluidics is expanding due to a number of important factors. The growing requirement for point-of-care diagnostics is one of an important factor. The necessity for fast and accurate diagnosis has risen due to the increase in chronic diseases like cancer and diabetes, which is propelling the application of microfluidics in healthcare. Furthermore, the use of microfluidic devices is increasing due to innovations in drug delivery , organ-on-a-chip technology, and personalized medicine. Additionally, the market is driven by the rise in proteomics and genomics associated research.

"Polymers to account for largest market share in 2023."

The market for microfluidics is propelled by polymers because of their their low costs, ease of production and adaptability. Microfluidic device manufacturing often requires polymers such as polydimethylsiloxane (PDMS), polymethyl methacrylate (PMMA), and cyclic olefin copolymer (COC). These polymers are helpful in the fabrication of microfluidic channels and structures. Moreover, as compared to conventional materials like silicon or glass, polymers are easier to mold and also, enables cheaper manufacturing costs. The biocompatible property of polymers makes them useful for a variety of medical applications, including medication delivery, lab-on-a-chip, and diagnostics. Due to such advantages, polymers accounts for the largest share in the microfluidics market.

"Hospital and Diagnostic Centers to register highest growth rate in the market during the forecast period."

Various significant factors are propelling the growth of hospitals and diagnostic centers in the microfluidics industry. One important factor is the rising requirement for point-of-care diagnostics, as they provides quick, on-site testing that improves patient outcomes. Microfluidics play a major role in this positive outcome as it offers faster and precise result . Moreover, the requirement for efficacious diagnostics in clinical settings has risen due to the increase in infectious diseases like COVID-19. These equipment decreases cost, expedites testing methods, and improve precision and accuracy of diagnosis.

"Asia Pacific to register highest growth rate in the market during the forecast period."

The highest CAGR was registered by the APAC region throughout the forecast period from 2024-2029. Asia Pacific comprise India, China, Japan, Australia, South Korea and RoAPAC. The demand for innovative technologies is increasing, especially in China, India, and Japan. Microfluidic devices for diagnostic and therapeutic applications are used due to the rise in prevalence of chronic and infectious diseases and the increase in focus on early diagnosis and preventative healthcare. The region's rising pharmaceutical and lifesciences industries are also undertaking research and development initiatives, which increases the requirement for microfluidics in personalized medicine and drug discovery.

A breakdown of the primary participants referred to for this report is provided below:

- By Company Type: Tier 1-30%, Tier 2-42%, and Tier 3-28%
- By Designation: C-level-- 14%, Director-level-10%, and Others-76%

- By Region: North America-40%, Europe-30%, Asia Pacific-22%, Rest of the World -8%.

Prominent players in this market are Abbott laboratories (US), Agilent Technologies, Inc. (US), Aignep S.P.A (Italy), biomerieux (France), BD(US), Bio-Rad laboratories, Inc (US), Danaher Corporation (US), Illumina Inc. (US), Parker Hannifin Coporation (US), Thermo Fisher Scientific Inc. (US), SMC Corporation (Japan), Idex Corporation (US), Fortive Corporation (US), Perkinelmer, Inc. (US), F.Hoffmann-LA Roche Ltd (Switzerland), Standard Biotools Inc. (US), Quidelortho Corporation (US), Hologic Inc. (US), Dolomite Microfluidics (UK) and Elveflow (France).

### Research Coverage

The report comprise segmentation that covers end users, products, applications, and geographic regions. It also covers the key drivers, restraints, opportunities, and challenges impacting the growth trajectory of the microfluidics market. The research offers stakeholders an in-depth analysis of market potential and challenges, with a focus on major players and competitive landscapes. Moreover, micromarkets are analysed as per their overall impact to the global microfluidics sector, growth patterns, and potential. The analysis forecasts rise in market segment revenues, focusing on five key regions.

Key Benefits of Buying the Report:

The purpose of this research is to assist both new and existing players in the microfluidics market to assess the sustainability of their investments by providing detailed and knowledgeable information. It offers a dataset to assist in making key decisions. This report's potential to facilitate thorough risk evaluation and provide direction for investment decisions is one of its major benefit. Market segmentation according to end-users and geographical areas is provided in the study, that provides precise analysis and insights. It also provide significant trends, obstacles, opportunities, and drivers, giving stakeholders the information they require to make strategic decisions that help in their long-term growth.

The report provides the insights on the following pointers:

Analysis of the key drivers, restraints, opportunities, and challenges affecting the microfluidics market growth: Innovative technology and increase in prevalence of chronic diseases ; increased cost of devices and stringent regulations ; increase in number of diagnostic centers.

Product Development/Innovation: Overview of technologies, research & development ventures and launch of innovative product & service for the microfluidics industry.

Market Development: Details associated with profitable markets: this research studies the microfluidics business in various geographical regions.

Market Diversification: In-depth understanding of innovative products, unexamined regions, recent developments, and expenditures in the microfluidics market.

Competitive Assessment: Detailed analysis of market share, services and products offered and key strategies adopted by prominent players such as Danaher Corporation (US), Illumina Inc. (US), biomerieux (France), Thermo Fisher Scientific Inc. (US) and Abbott laboratories (US).

### **Table of Contents:**

1⊓INTRODUCTION⊓30 1.1 STUDY OBJECTIVES 30 1.2 MARKET DEFINITION 30 1.3 MARKET SCOPE 31 1.3.1 MARKETS COVERED 31 1.3.2 INCLUSIONS & EXCLUSIONS 32 1.3.3 ||YEARS CONSIDERED || 33 1.3.4 CURRENCY CONSIDERED 33 1.4 MARKET STAKEHOLDERS 33 1.5 SUMMARY OF CHANGES 34 2 RESEARCH METHODOLOGY 36 2.1 RESEARCH DATA 36 2.2 RESEARCH DESIGN 36 2.2.1 SECONDARY RESEARCH 37 2.2.1.1 Key data from secondary sources 38 2.2.2 PRIMARY RESEARCH 39 2.2.2.1 Key industry insights 40 2.3 MARKET SIZE ESTIMATION METHODOLOGY 41 2.3.1 BOTTOM-UP APPROACH 42 2.3.1.1 Approach 1: Company revenue estimation approach 43 2.3.1.2 Approach 2: Customer-based market estimation 44 2.3.1.3 Approach 3: Top-down approach 45 2.3.1.4 Approach 4: Primary interviews 45 2.3.1.5 Growth forecast 45 2.3.1.6 CAGR projection 46 2.3.2 TOP-DOWN APPROACH 46 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 47 2.5 MARKET SHARE ASSESSMENT 48 2.6 RESEARCH ASSUMPTIONS 48 2.7 RESEARCH LIMITATIONS 49 2.8⊓RISK ASSESSMENT∏49 3 EXECUTIVE SUMMARY 50 4 PREMIUM INSIGHTS 54

4.1 MICROFLUIDICS MARKET OVERVIEW 54

4.2 ASIA PACIFIC: MICROFLUIDICS MARKET, BY END USER AND COUNTRY (2023) 55 4.3 MICROFLUIDICS MARKET, BY REGION 56 4.4 GEOGRAPHIC SNAPSHOT OF MICROFLUIDICS MARKET 56 5 MARKET OVERVIEW 57 5.1 INTRODUCTION 57 5.2 MARKET DYNAMICS 57 5.2.1 DRIVERS 58 5.2.1.1 Growing requirement for point-of-care testing 58 5.2.1.2 Rising technological advancements 58 5.2.1.3 Increasing focus on data precision and accuracy 59 5.2.1.4 Economic benefits associated with microfluidics 60 5.2.1.5 Portability with microfluidic chip miniaturization 60 5.2.1.6 Rising demand for effective sample analysis 61 5.2.2 RESTRAINTS 61 5.2.2.1 Stringent regulatory approval process 61 5.2.2.2□Integration of microfluidics into current workflow□62 5.2.3 OPPORTUNITIES 62 5.2.3.1 Emergence of 3D cell culture systems 62 5.2.3.2 Growth potential of emerging economies 63 5.2.3.3 Use of microfluidics in life sciences & pharmaceutical industries 64 5.2.4 CHALLENGES 65 5.2.4.1 Low adoption of microfluidic devices among end users 65 5.3⊓INDUSTRY TRENDS⊓65 5.3.1 E-HEALTH DIAGNOSTICS 65 5.3.2 INTEGRATION OF MICROFLUIDICS WITH 3D PRINTING 66 5.3.3□R&D INVESTMENTS FOR PRODUCT DEVELOPMENT□66 5.4 PORTER'S FIVE FORCES ANALYSIS 69 5.4.1 THREAT OF NEW ENTRANTS 70 5.4.2 THREAT OF SUBSTITUTES 70 5.4.3 BARGAINING POWER OF SUPPLIERS 70 5.4.4 BARGAINING POWER OF BUYERS 70 5.4.5 INTENSITY OF COMPETITIVE RIVALRY 71 5.5 KEY STAKEHOLDERS & BUYING CRITERIA 5.5.1 KEY STAKEHOLDERS IN BUYING PROCESS 71 5.5.2 BUYING CRITERIA 72 5.6 REGULATORY LANDSCAPE 72 5.6.1 NORTH AMERICA 72 5.6.1.1 US 72 5.6.1.2 Canada 74 5.6.2 UROPE 75 5.6.3 ASIA PACIFIC 76 5.6.3.1[]apan[]76 5.6.3.2 China 77 5.6.3.3 || India || 78 5.6.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 5.7 REIMBURSEMENT SCENARIO 81 5.8 ECOSYSTEM ANALYSIS 82

5.9 VALUE CHAIN ANALYSIS 84 5.9.1 RESEARCH & DEVELOPMENT 84 5.9.2 RAW MATERIAL PROCUREMENT & MANUFACTURING 85 5.9.3 MARKETING & SALES, DISTRIBUTION, AND POST-SALES SERVICES 85 5.10 SUPPLY CHAIN ANALYSIS 86 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 87 5.12 IMPACT OF GEN AI ON MICROFLUIDICS MARKET 88 5.13 PATENT ANALYSIS 89 5.13.1 PATENT PUBLICATION TRENDS FOR MICROFLUIDICS 89 5.13.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 89 5.14 TRADE ANALYSIS 95 5.14.1 IMPORT DATA 95 5.14.2 EXPORT DATA (HS CODE 3822) 96 5.14.3 EXPORT DATA (HS CODE 8479) 96 5.15 TECHNOLOGY ANALYSIS 97 5.15.1 KEY TECHNOLOGIES 97 5.15.1.1 Biosensor elements 97 5.15.1.2 Materials science 98 5.15.1.3 Microfabrication 98 5.15.1.4 Direct-writing 99 5.15.1.5 Optofluidics 99 5.15.1.6 Acoustofluidics 99 5.15.2 COMPLEMENTARY TECHNOLOGIES 100 5.15.2.1 MEMS 100 5.15.2.1.1 Green microfluidics 100 5.15.2.1.2 Microsensors/transducers 100 5.15.3 ADJACENT TECHNOLOGIES 101 5.15.3.1 3D inkjet printing 101 5.15.3.2 Lab-on-fiber 101 5.16 KEY CONFERENCES & EVENTS 102 5.17 PRICING ANALYSIS 103 5.17.1 AVERAGE SELLING PRICE TREND, BY REGION 103 5.17.2 AVERAGE SELLING PRICE OF TOP 3 APPLICATIONS, BY KEY PLAYER 105 5.18 UNMET NEEDS/END-USER EXPECTATIONS 106 5.19 CASE STUDY ANALYSIS 106 5.19.1 CASE STUDY 1: MULTIPLEX MICROFLUIDIC CIRCUIT FOR BLOOD VESSEL-ON-A-CHIP PERFUSION USING FLOWEZ 106 5.19.2 CASE STUDY 2: MICROFLUIDIC SYSTEM FOR ROBOTIC HAND PLAYING NINTENDO 5.19.3 CASE STUDY 3: 3D-PRINTED MICROFLUIDIC DEVICES USING POLYJET TECHNOLOGY 108 5.20 INVESTMENT & FUNDING SCENARIO 109 6⊓MICROFLUIDICS MARKET, BY PRODUCT⊓111 6.1⊓INTRODUCTION⊓112 6.2 MICROFLUIDICS-BASED DEVICES 112 6.2.1∏HIGH UPTAKE OF POC TESTING AND ORGAN-ON-A-CHIP SYSTEMS TO PROPEL MARKET∏112 6.3 MICROFLUIDIC COMPONENTS 113 6.3.1 MICROFLUIDIC COMPONENTS, BY TYPE 114 6.3.1.1 Microfluidic chips 115 6.3.1.1.1 Chips to account for largest share of components market 115

- 6.3.1.2 Flow & pressure sensors 117
- 6.3.1.2.1 Utilization in lab diagnostics & research applications to drive market 117
- 6.3.1.3 Flow & pressure controllers 119
- 6.3.1.3.1 Cost-effectiveness and durability to boost demand 119
- 6.3.1.4 Microfluidic valves 120
- 6.3.1.4.1 Technological advancements to support market growth 120
- 6.3.1.5 Micropumps 124
- 6.3.1.5.1 Wide usage in drug delivery and glucose injections to fuel uptake 124
- 6.3.1.6[Microneedles[]126
- 6.3.1.6.1 Miniscule size and painless patch application procedure to boost demand 126
- 6.3.1.7 Other microfluidic components 127
- 6.3.2 MICROFLUIDIC COMPONENTS, BY MATERIAL 128
- 6.3.2.1[]Silicon[]128
- 6.3.2.1.1 High precision and durability to boost demand 128
- 6.3.2.2 Polymers 129
- 6.3.2.2.1 Polymethyl methacrylate (PMMA) 130
- 6.3.2.2.1.1 Durable alternative to glass to fuel uptake 130
- 6.3.2.2.2 Polydimethylsiloxane (PDMS) 131
- 6.3.2.2.2.1 Limited compatibility with specific solvents and acids to limit market adoption 131
- 6.3.2.2.3 Cyclic olefin copolymers 131
- 6.3.2.2.3.1 Low water absorption and enhanced electrical insulation properties to boost demand 131
- 6.3.2.2.4 Other polymers 132
- 6.3.2.3[Glass[]133
- 6.3.2.3.1 High cost and brittleness to restrain market 133
- 7 MICROFLUIDICS MARKET, BY APPLICATION 135
- 7.1 INTRODUCTION 136
- 7.2[]IVD[]136
- 7.2.1 CLINICAL DIAGNOSTICS 138
- 7.2.1.1 Growing focus on early disease detection to drive market 138
- 7.2.2 POINT-OF-CARE TESTING (POCT) 139
- 7.2.2.1 High uptake of lab-on-a-chip technologies to fuel uptake 139
- 7.2.3 VETERINARY DIAGNOSTICS 140
- 7.2.3.1 Detection of toxins in food through LOC systems to support market growth 140
- 7.3 PHARMACEUTICAL & LIFE SCIENCE RESEARCH 141
- 7.3.1 LAB ANALYTICS 142
- 7.3.1.1 Proteomic analysis 143
- 7.3.1.1.1 Utilization of lab-on-a-chip devices for therapeutic development to drive market 143
- 7.3.1.2 Genomic analysis 144
- 7.3.1.2.1 Growing focus on NGS and digital PCR to boost demand 144
- 7.3.1.3 Cell-based assays 145
- 7.3.1.3.1 Drug screening for cross-reaction & toxicity testing to support market growth 145
- 7.3.1.4 Capillary electrophoresis 146
- 7.3.1.4.1 Growing applications for environmental monitoring and clinical diagnostics to fuel uptake 146
- 7.3.2 MICRODISPENSING 147
- 7.3.2.1 Suitability for low-viscosity applications to support market growth 147
- 7.3.3 MICROREACTORS 148
- 7.3.3.1 ] High uptake by leading companies for process optimization to fuel market ] 148

7.4 THERAPEUTICS 149 7.4.1 DRUG DELIVERY 150 7.4.1.1 Utilization of microneedles for painless and precise delivery to drive market 150 7.4.2 WEARABLE DEVICES 151 7.4.2.1 Integration of microfluidics-based wearable devices to support market growth 151 8 MICROFLUIDICS MARKET, BY END USER 153 8.1 INTRODUCTION 154 8.2 HOSPITALS AND DIAGNOSTIC CENTERS 154 8.2.1 AVAILABILITY OF TECHNOLOGICALLY ADVANCED EQUIPMENT AND FOCUS ON EARLY DISEASE DIAGNOSIS TO BOOST DEMAND<sub>154</sub> 8.3 ACADEMIC & RESEARCH INSTITUTES 155 8.3.1 ⊓INVESTMENTS IN BIOMEDICAL & LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH 155 8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 158 8.4.1 GROWING FOCUS ON BIOMARKER & DRUG DISCOVERY TO PROPEL MARKET 9 MICROFLUIDICS MARKET, BY REGION 160 9.1 INTRODUCTION 161 9.2 NORTH AMERICA 161 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 162 9.2.2 US 168 9.2.2.1 High healthcare expenditure and wide adoption of technologically advanced products to drive market 168 9.2.3 CANADA 170 9.2.3.1 Government funds and focus on research to support market growth 170 9.3⊓EUROPE⊓172 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 172 9.3.2 GERMANY 177 9.3.2.1 Growing focus on proteomics & genomics research to drive market 177 9.3.3 || FRANCE || 179 9.3.3.1 Favorable government support for R&D to drive market 179 9.3.4[]UK[]182 9.3.4.1 Rising cases of chronic diseases and increasing demand for POC testing to boost demand 9.3.5 || ITALY || 184 9.3.5.1 Innovative development of microfluidic chips to boost demand 184 9.3.6 SPAIN 186 9.3.6.1 Growth in pharmaceutical industry to fuel uptake 186 9.3.7 REST OF EUROPE 188 9.4 ASIA PACIFIC 190 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 190 9.4.2 CHINA 197 9.4.2.1 Growing focus on nanotechnology to drive market 197 9.4.3 || APAN || 199 9.4.3.1 [High investments in academic research activities to propel market 199 9.4.4 INDIA 201 9.4.4.1 Increasing prevalence of CVD and diabetes to support market growth 201 9.4.5 AUSTRALIA 204 9.4.5.1 Rising incidence of infectious diseases to fuel uptake 204 9.4.6 SOUTH KOREA 206 9.4.6.1 Increasing R&D expenditure to drive growth 206

9.4.7 REST OF ASIA PACIFIC 209 9.5 LATIN AMERICA 210 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 210 9.5.2[BRAZIL]215 9.5.2.1 Increasing development of disease diagnostics kits to fuel uptake 215 9.5.3 MEXICO 217 9.5.3.1 Rising prevalence of chronic diseases to boost demand for POC testing 9.5.4 REST OF LATIN AMERICA 219 9.6 MIDDLE EAST & AFRICA 221 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 222 9.6.2 GCC COUNTRIES 226 9.6.2.1 Adoption of advanced microfluidic devices to support market growth 226 9.6.3 REST OF MIDDLE EAST & AFRICA 228 10 COMPETITIVE LANDSCAPE 231 10.1 INTRODUCTION 231 10.2□KEY PLAYER STRATEGY/RIGHT TO WIN□231 10.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MICROFLUIDICS MARKET 231 10.4 REVENUE ANALYSIS, 2019?2023 232 10.5 MARKET SHARE ANALYSIS, 2023 233 10.6 RANKING OF KEY MARKET PLAYERS 235 10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 235 10.7.1[]STARS[]235 10.7.2 EMERGING LEADERS 235 10.7.3 PERVASIVE PLAYERS 236 10.7.4 PARTICIPANTS 236 10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 237 10.7.5.1 Company footprint 237 10.7.5.2 Product footprint 238 10.7.5.3 Application footprint 239 10.7.5.4 End-user footprint 240 10.7.5.5 Region footprint 241 10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 242 10.8.1 PROGRESSIVE COMPANIES 242 10.8.2 RESPONSIVE COMPANIES 242 10.8.3 DYNAMIC COMPANIES 242 10.8.4 STARTING BLOCKS 242 10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 244 10.8.5.1 Detailed list of key startup/SME players 244 10.8.5.2 Competitive benchmarking of key emerging players/startups 245 10.9 COMPANY VALUATION & FINANCIAL METRICS 246 10.9.1 FINANCIAL METRICS 246 10.9.2 COMPANY VALUATION 246 10.10 BRAND/PRODUCT COMPARATIVE ANALYSIS 247 2 10.11 COMPETITIVE SCENARIO 248 10.11.1 PRODUCT LAUNCHES & APPROVALS 248 10.11.2 DEALS 249

10.11.3 EXPANSIONS 250 10.11.4 OTHER DEVELOPMENTS 250 11 COMPANY PROFILES 251 11.1 KEY PLAYERS 251 11.1.1 DANAHER CORPORATION 251 11.1.1.1 Business overview 251 11.1.1.2 Products offered 253 11.1.1.3 Recent developments 254 11.1.1.3.1 Deals 254 11.1.1.3.2 Expansions 255 11.1.1.4 MnM view 255 11.1.1.4.1 Key strengths 255 11.1.1.4.2 Strategic choices 255 11.1.1.4.3 Weaknesses & competitive threats 255 11.1.2 ILLUMINA, INC. 256 11.1.2.1 Business overview 256 11.1.2.2 Products offered 258 11.1.2.3 Recent developments 259 11.1.2.3.1 Product launches & approvals 259 11.1.2.3.2 Deals 259 11.1.2.4[MnM view]261 11.1.2.4.1 Key strengths 261 11.1.2.4.2 Strategic choices 261 11.1.2.4.3 Weaknesses & competitive threats 261 11.1.3 BIOMERIEUX 262 11.1.3.1 Business overview 262 11.1.3.2 Products offered 264 11.1.3.3 Recent developments 264 11.1.3.3.1 Product launches & approvals 264 11.1.3.3.2 Deals 265 11.1.3.4 MnM view 265 11.1.3.4.1 Key strengths 265 11.1.3.4.2 Strategic choices 265 11.1.3.4.3 Weaknesses & competitive threats 265 11.1.4 THERMO FISHER SCIENTIFIC INC. 266 11.1.4.1 Business overview 266 11.1.4.2 Products offered 268 11.1.4.3 Recent developments 269 11.1.4.3.1 Product launches & approvals 269 11.1.4.3.2 Deals 271 11.1.4.3.3 Expansions 272 11.1.4.4 MnM view 272 11.1.4.4.1 Key strengths 272 11.1.4.4.2 Strategic choices 272 11.1.4.4.3 Weaknesses & competitive threats 272 11.1.5 ABBOTT LABORATORIES 273 11.1.5.1 Business overview 273

11.1.5.2 Products offered 275 11.1.5.3 MnM view 276 11.1.5.3.1 Key strengths 276 11.1.5.3.2 Strategic choices 276 11.1.5.3.3 Weaknesses & competitive threats 276 11.1.6 PARKER HANNIFIN CORP 277 11.1.6.1 Business overview 277 11.1.6.2 Products offered 279 11.1.7 SMC CORPORATION 282 11.1.7.1 Business overview 282 11.1.7.2 Products offered 283 11.1.7.3 Recent developments 286 11.1.7.3.1 Product launches 286 11.1.8 IDEX CORPORATION 289 11.1.8.1 Business overview 289 11.1.8.2 Products offered 291 11.1.8.3 Recent developments 292 11.1.8.3.1 Deals 292 11.1.9[FORTIVE[293 11.1.9.1 Business overview 293 11.1.9.2 Products offered 295 11.1.10 REVVITY, INC. 297 11.1.10.1 Business overview 297 11.1.10.2 Products offered 298 11.1.10.3 Recent developments 300 11.1.10.3.1 Deals 300 11.1.11 AGILENT TECHNOLOGIES, INC. 301 11.1.11.1 Business overview 301 11.1.11.2 Products offered 303 11.1.11.3 Recent developments 304 11.1.11.3.1 Product launches 304 11.1.11.3.2 Deals 305 11.1.11.3.3 Expansions 305 11.1.12 BIO-RAD LABORATORIES, INC. 306 11.1.12.1 Business overview 306 11.1.12.2 Products offered 308 11.1.12.3 Recent developments 309 11.1.12.3.1 Product launches 309 11.1.12.3.2 Deals 310 11.1.13 BECTON, DICKINSON AND COMPANY 311 11.1.13.1 Business overview 311 11.1.13.2 Products offered 313 11.1.13.3 Recent developments 315 11.1.13.3.1 Product launches & approvals 315 11.1.13.3.2 Deals 316 11.1.13.3.3 Expansions 317 11.1.14 F. HOFFMANN-LA ROCHE LTD. 318

11.1.14.1 Business overview 318 11.1.14.2 Products offered 319 11.1.14.3 Recent developments 320 11.1.14.3.1 Product launches & approvals 320 11.1.14.3.2 Deals 321 11.1.15 STANDARD BIOTOOLS 322 11.1.15.1 Business overview 322 11.1.15.2 Products offered 324 11.1.15.3 Recent developments 325 11.1.15.3.1 Product launches & approvals 325 11.1.15.3.2 Deals 326 11.1.16 QUIDELORTHO CORPORATION 327 11.1.16.1 Business overview 327 11.1.16.2 Products offered 329 11.1.16.3 Recent developments 330 11.1.16.3.1 Product approvals 330 11.1.16.3.2 Deals 331 11.1.16.3.3 Expansions 331 11.1.17 HOLOGIC, INC. 332 11.1.17.1 Business overview 332 11.1.17.2 Products offered 334 11.1.17.3 Recent developments 334 11.1.17.3.1 Product approvals 334 11.1.17.3.2 Deals 334 11.1.18 AIGNEP S.P.A. 335 11.1.18.1 Business overview 335 11.1.18.2 Products offered 336 11.1.18.3 Recent developments 336 11.1.18.3.1 Deals 336 11.1.19 DOLOMITE MICROFLUIDICS 337 11.1.19.1 Business overview 337 11.1.19.2 Products offered 338 11.1.19.3 Recent developments 342 11.1.19.3.1 Product launches & approvals 342 11.1.19.3.2 Deals 342 11.1.19.3.3 Other developments 342 11.1.20[]ELVEFLOW[]343 11.1.20.1 Business overview 343 11.1.20.2 Products offered 343 11.2 OTHER PLAYERS 345 11.2.1 NANOSTRING TECHNOLOGIES 345 11.2.2 INNOVATIVE BIOCHIPS, LLC 346 11.2.3 FLUIDIC ANALYTICS 347 11.2.4 UFLUIDIX 348 11.2.5 HORIBA 349 11.2.6 MICRONIT B.V. 350 11.2.7 EMULATE INC. 351

11.2.8 SPHERE FLUIDICS LIMITED 352

11.2.9 ZEON CORPORATION 353

11.2.10 QIAGEN N.V. 354

12[]APPENDIX[]355

12.1 DISCUSSION GUIDE 355

12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 361

12.3 CUSTOMIZATION OPTIONS 363

12.4 RELATED REPORTS 363

12.5 AUTHOR DETAILS 364



# Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application (Diagnostics (Clinical, PoC), Research (Proteomic, Genomics, Cell), Therapeutics (Drug Delivery, Wearables)), End User- Global Forecast to 2029

Market Report | 2025-02-01 | 365 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

### **ORDER FORM:**

| Select license | License                 |       | Price      |
|----------------|-------------------------|-------|------------|
|                | Single User             |       | \$4950.00  |
|                | Multi User              |       | \$6650.00  |
|                | Corporate License       |       | \$8150.00  |
|                | Enterprise Site License |       | \$10000.00 |
|                |                         | VAT   |            |
|                |                         | Total |            |

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

| Email*        | Phone*                |         |
|---------------|-----------------------|---------|
| First Name*   | Last Name*            |         |
| Job title*    |                       |         |
| Company Name* | EU Vat / Tax ID / NIP | number* |
| Address*      | City*                 |         |

| Zip  | Code* |
|------|-------|
| - 10 | Couc  |

Country\*

Date

Signature

2025-05-19